IP Library Granted Patent US 6,929,924
Granted Patent B2
US 6,929,924 · App. 10/792,395 · Granted Aug 16, 2005

C-peptide specific assay procedure

Assignee: Pasteur Sanofi Diagnostics
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 6,929,924
App. No.
10/792,395
Granted
Aug 16, 2005
Kind
B2
Abstract

The present invention relates to a specific C-peptide assay method which can eliminate all interference due to proinsulin and its intermediates, in particular des-31,32-proinsulin and/or des-64,65-proinsulin. It also relates to antibodies for carrying out this assay.

Claims (26)

1. A method for assaying C-peptide in a sample suspected of containing C-peptide, intact proinsulin, des-31,32 proinsulin, and/or des-64,65-proinsulin comprising:

a) contacting the sample with at least a first anti-peptide antibody which specifically binds an epitope present entirely in the C-peptide and a second antibody which is selected from:

an anti-proinsulin antibody which is specific to intact proinsulin and des-31,32-proinsulin and recognizes an epitope located in an intact A-chain-C-peptide (AC) junction of proinsulin and des-31,32 proinsulin, said anti-proinsulin AC junction antibody epitope being either adjacent to or overlapping with the epitope of said at least one anti-C-peptide antibody, or

an anti-proinsulin antibody which is specific to intact proinsulin and des-64,65-proinsulin and recognizes an epitope located in an intact B-chain-C-peptide (BC) junction of proinsulin and des-64,65-proinsulin, said anti-proinsulin BC junction antibody epitope being either adjacent to or overlapping with the epitope of said at least one anti-C-peptide antibody, or

a mixture of said anti-proinsulin AC junction antibody and said anti-proinsulin BC junction antibody under conditions such that said at least one anti-C-peptide antibody binds to C-peptide in the sample, binding of the anti-proinsulin AC junction antibody to any proinsulin and/or des-31,32-proinsulin interferes with binding of said at least one anti-C-peptide antibody to intact proinsulin and des-31,32-proinsulin in the sample, and/or binding of the anti-proinsulin BC junction antibody to any proinsulin and/or des-64,65-proinsulin interferes with binding of said at least one anti-C-peptide antibody to intact proinsulin and des-64,65-proinsulin in the sample; and

b) detecting amount of C-peptide bound to said at least one anti-C-peptide antibody in said contacted sample as an assay of the amount of C-peptide in the sample.

2. The method according to claim 1 , wherein said epitope located in the AC junction of proinsulin and des-31,32-proinsulin includes a peptide sequence: Lys Arg.

3. The method according to claim 1 , wherein said epitope located in the AC junction of proinsulin and des-31,32-proinsulin includes a peptide sequence:

Leu Gln Lys Arg Gly Ile Val Glu (SEQ ID NO: 3).

4. The method according to claim 1 , wherein said epitope located in the AC junction of proinsulin and des-31,32-proinsulin includes a peptide sequence:

Leu Gln Lys Arg Gly Ile Val Glu Gln (SEQ ID NO: 4).

5. The method according to claim 1 , wherein said epitope located in the BC junction of proinsulin and des-64,65-proinsulin includes a peptide sequence: Arg Arg.

6. The method according to claim 1 , wherein the sequence of said epitope located in the BC junction of proinsulin and des-64,65-proinsulin is selected from the group consisting of:

Phe Tyr Thr Pro Lys Thr Arg Arg Glu Ala Glu Asp Leu Gln Val (SEQ ID NO: 5)

Thr Pro Lys Thr Arg Arg Glu Ala Glu Asp Leu Gln Val (SEQ ID NO: 2); and

Phe Tyr Thr Pro Lys Thr Arg Arg Glu Ala Glu Asp Leu (SEQ ID NO: 6).

7. The method according to claim 1 comprising:

a) contacting the sample with the anti-C-peptide antibody and an anti-proinsulin antibody which is specific to intact proinsulin and des-31,32-proinsulin and recognizes an epitope located in the AC junction of proinsulin and des-31,32-proinsulin, said proinsulin AC junction epitope either being adjacent or overlapping the epitope of said anti-C-peptide antibody, thus interfering with binding of the anti-C-peptide antibody to intact proinsulin and des-31,32-proinsulin and

b) detecting the amount of C-peptide bound to said anti-C-peptide antibody.

8. The method according to claim 1 comprising:

a) contacting the sample with the anti-C-peptide antibody and an anti-proinsulin antibody which is specific to intact proinsulin and des-64,65-proinsulin and recognizes an epitope located in the BC junction of proinsulin and des-64,65-proinsulin, said proinsulin BC junction epitope either being adjacent or overlapping the epitope of said anti-C-peptide antibody, thus interfering with binding of the anti-C-peptide antibody to intact proinsulin and des-64,65-proinsulin and

b) detecting the amount of C-peptide bound to said anti-C-peptide antibody.

9. The method according to claim 1 in which at least one of said antibodies is a monoclonal antibody.

10. The method according to claim 1 in which the sample is obtained from serum, plasma, or urine.

11. The method according to claim 1 , said method being a sandwich assay.

12. The method according to claim 1 , said method being a competitive radioimmunological assay.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 8, 2019
From: BIO-RAD INNOVATIONS
To: BIO-RAD EUROPE GMBH
Reel/Frame 049122/0754 →
CORRECTIVE ASSIGNMENT TO CORRECT THE INCORRECT APPL. NO. 12/056,432 PREVIOUSLY RECORDED AT REEL: 027668 FRAME: 0693. ASSIGNOR(S) HEREBY CONFIRMS THE CHANGE OF NAME. Recorded Mar 6, 2015
From: BIO-RAD PASTEUR
To: BIO-RAD INNOVATIONS
Reel/Frame 035224/0856 →
CHANGE OF NAME Recorded Feb 7, 2012
From: PASTEUR SANOFI DIAGNOSTICS
To: BIO-RAD PASTEUR
Reel/Frame 027668/0585 →
CHANGE OF NAME Recorded Feb 7, 2012
From: BIO-RAD PASTEUR
To: BIO-RAD INNOVATIONS
Reel/Frame 027668/0693 →
Priority Claims (1)
FR 97 07730 · Jun 20, 1997 · national
Continuity (2)
Continuation 0944636000
Related Publication 20050037448A1 · Feb 17, 2005